On CAR-T’s edge, Seattle researchers plot to bypass Novartis therapy – 9.19.2017 – Xconomy
It’s not a stretch to say that Greta Oberhofer is alive thanks to the genetically modified cell therapy called CAR-T. But the Novartis CAR-T wasn’t what cured Greta; her parents enrolled her in a study for a different CAR-T program, at Seattle Children’s Hospital, which was accepting patients as young as a year old. Three years later with no relapse, Greta is one of the lucky ones. The dim outlook for many others, however, has spurred Drs. Mike Jensen, Rebecca Gardner, Colleen Annesley, and their colleagues to press on with more cutting-edge versions of CAR-T that they hope in a few years are not just replacements for the Novartis therapy, but alternatives to bone marrow transplants.
Promising drug combination silences the rage of graft-versus-host disease – 9.20.2017 – On the Pulse
For nearly 180 days, London Bowater stayed in Seattle Children’s Cancer Unit with graft-versus-host disease (GVHD), which she developed after a cord blood transplant for acute lymphoblastic leukemia. Building on a decade of work dedicated to finding the right combination of therapies to prevent GVHD, there is promising new research underway by Dr. Leslie Kean, associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute, and a research scientist in her lab, Dr. Victor Tkachev. London, now 10, overcame GVHD with access to another experimental therapy that Dr. Paul Carpenter of Seattle Children’s obtained through compassionate use.
Kymab and Seattle Children's Research Institute publish impressive results using Kymab's KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine – 8.08.2017 – Yahoo! Finance
Kymab announced that new data published in Science Translational Medicine indicate that Kymab's most advanced clinical stage antibody, KY1005, could play an important role in blood-system transplants, such as the treatment of leukemia. Researchers from Kymab worked with a team led by Dr. Leslie Kean, associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute. "KY1005, in combination with sirolimus, sets a new standard for aGVHD prevention," commented Kean. "These results in the complex and clinically relevant animal model suggest this regimen is an exceptional candidate for clinical translation."